Akili, Inc.: restructuring charge — Akili shifts to non-prescription model, cuts workforce 40%, extends cash runway to 2H 2025

Akili, Inc.

Workforce reduced ~40%; field sales and market access teams eliminated, representing ~2/3 of cuts. Severance cost estimated $2.3–2.8M.
EndeavorOTC generated 125,971 first-time downloads, 4,170 active subscribers, $81.88 ARPU in first three months.
2023 non-GAAP total opex guidance $55–60M; 2024 non-GAAP opex $42–47M.
Cash, cash equivalents, and short-term investments expected to fund operations into 2H 2025.
Non-prescription model expected to achieve 60–70% gross margins by late 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Akili, Inc. announced a restructuring with charges of approximately $2.3 – $2.8 million affecting the Company (approximately 40%).

Type: restructuring
Charge: approximately $2.3 – $2.8 million
Affected area: the Company
Headcount: approximately 40%

Exact text from the filing

of 2023. Affected employees will be offered severance and other benefits, and the Company estimates that these severance and termination-related costs will be approximately $2.3 – $2.8 million and expects to record these charges in the third quarter of 2023. The Company also expects that payments of most of these costs will be made in 2023. As a result of

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-23-233939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.